Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy

Overview

Journal Acta Derm Venereol

Specialty Dermatology

Date 2020 Jun 9

PMID 32511739

Citations 4

Authors

Georgios Kokolakis

Frank Bachmann

Kerstin Wolk

Robert Sabat

Sandra Philipp

Affiliations

Soon will be listed here.

Abstract

Psoriatic nail symptoms are frequent in psoriasis, affecting up to 80% of patients. Therapy responses to nail symptoms are often limited. In this multicentre non-interventional prospective study, 267 patients with nail involvement were treated with adalimumab for a period of 24 months. The efficacy of adalimumab for nail psoriasis was evaluated and predictors for better response were identified. For statistical analysis Kolmogorov-Smirnoff, Mann-Whitney U, Wilcoxon, χ2 and two-tailed Spearman's rank correlation tests were applied. After 3 and 6 months, reductions in Nail Psoriasis Severity Index (NAPSI) of 32.8% (p < 0.001) and almost 50% (p < 0.001), respectively, were observed, compared with baseline scores (mean NAPSI score, 34.2 ± 1.3). In 6 months, 60.0% of patients achieved NAPSI50, 36.4% NAPSI75, and 21.7% NAPSI90. Approximately 42% and 60% of patients achieved NAPSI90 after 12 and 24 months, respectively. At month 12, reduction in NAPSI significantly correlated with improvement in Dermatological Life Quality Index. Stratification by age, sex, and body mass index indicated that treatment was more effective in younger patients and those with higher body mass index. Adalimumab is an effective long-term therapy for nail psoriasis. The amelioration of nail symptoms correlates with an improvements in the skin disease and quality of life.

Citing Articles

Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.

Forman C, Lipner S Indian Dermatol Online J. 2025; 16(1):50-58.

PMID: 39850668 PMC: 11753575. DOI: 10.4103/idoj.idoj_445_24.

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments.

Battista T, Scalvenzi M, Martora F, Potestio L, Megna M Clin Cosmet Investig Dermatol. 2023; 16:1899-1932.

PMID: 37519941 PMC: 10378542. DOI: 10.2147/CCID.S417679.

Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review.

Hwang J, Ricardo J, Lipner S Am J Clin Dermatol. 2023; 24(5):695-720.

PMID: 37209391 DOI: 10.1007/s40257-023-00786-4.

The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis-Real-World Data from Dermatology Practice.

Kokolakis G, Sabat R, Fischer I, Gomis-Kleindienst S, Fritz B, Burmester G J Pers Med. 2021; 11(11).

PMID: 34834435 PMC: 8620057. DOI: 10.3390/jpm11111083.

The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review.

Stewart C, Algu L, Kamran R, Leveille C, Abid K, Rae C Skin Appendage Disord. 2021; 7(2):83-89.

PMID: 33796553 PMC: 7991285. DOI: 10.1159/000512688.

References

Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A . Psoriatic arthritis in psoriatic patients. Br J Rheumatol. 1984; 23(4):246-50. DOI: 10.1093/rheumatology/23.4.246. View

Nast A, Boehncke W, Mrowietz U, Ockenfels H, Philipp S, Reich K . S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012; 10 Suppl 2:S1-95. DOI: 10.1111/j.1610-0387.2012.07919.x. View

Philipp S, Kokolakis G, Sabat R . [Systemic treatments for psoriasis and psoriatic arthritis]. Hautarzt. 2016; 67(6):464-71. DOI: 10.1007/s00105-016-3812-4. View

Gumusel M, Ozdemir M, Mevlitoglu I, Bodur S . Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol. 2010; 25(9):1080-4. DOI: 10.1111/j.1468-3083.2010.03927.x. View

van der Velden H, Klaassen K, van de Kerkhof P, Pasch M . Fingernail psoriasis reconsidered: a case-control study. J Am Acad Dermatol. 2013; 69(2):245-52. DOI: 10.1016/j.jaad.2013.02.009. View

Thaci D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y . Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2014; 29(2):353-360. DOI: 10.1111/jdv.12553. View

Treewittayapoom C, Singvahanont P, Chanprapaph K, Haneke E . The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study. J Am Acad Dermatol. 2012; 66(5):807-12. DOI: 10.1016/j.jaad.2011.12.015. View

Elewski B, Okun M, Papp K, Baker C, Crowley J, Guillet G . Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2017; 78(1):90-99.e1. DOI: 10.1016/j.jaad.2017.08.029. View

Vlachou C, Berth-Jones J . Nail psoriasis improvement in a patient treated with fumaric acid esters. J Dermatolog Treat. 2007; 18(3):175-7. DOI: 10.1080/09546630701264331. View

10.

Papp K, Reich K, Leonardi C, Kircik L, Chimenti S, Langley R . Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis.... J Am Acad Dermatol. 2015; 73(1):37-49. DOI: 10.1016/j.jaad.2015.03.049. View

11.

Langley R, Dauden E . Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology. 2010; 221 Suppl 1:29-42. DOI: 10.1159/000316179. View

12.

Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini B . Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol. 2009; 145(3):269-71. DOI: 10.1001/archdermatol.2008.600. View

13.

Reich K, Langley R, Papp K, Ortonne J, Unnebrink K, Kaul M . A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011; 365(17):1586-96. DOI: 10.1056/NEJMoa1010858. View

14.

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

15.

FREDRIKSSON T, Pettersson U . Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978; 157(4):238-44. DOI: 10.1159/000250839. View

16.

Rich P, Scher R . Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003; 49(2):206-12. DOI: 10.1067/s0190-9622(03)00910-1. View

17.

Crowley J, Weinberg J, Wu J, Robertson A, Van Voorhees A . Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2014; 151(1):87-94. DOI: 10.1001/jamadermatol.2014.2983. View

18.

Jiaravuthisan M, Sasseville D, Vender R, Murphy F, Muhn C . Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007; 57(1):1-27. DOI: 10.1016/j.jaad.2005.07.073. View

19.

Baran R . The burden of nail psoriasis: an introduction. Dermatology. 2010; 221 Suppl 1:1-5. DOI: 10.1159/000316169. View

20.

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C . Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015; 173(6):1387-99. DOI: 10.1111/bjd.14164. View